

## Product datasheet

# Human CREBBP knockout A549 cell line ab277885

### Overview

---

<b>Product name</b>	Human CREBBP knockout A549 cell line
<b>Parental Cell Line</b>	A549
<b>Organism</b>	Human
<b>Passage number</b>	<20
<b>Biosafety level</b>	1
<b>General notes</b>	<p><b>Recommended control:</b> Human wild-type A549 cell line (<a href="#">ab275463</a>). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.</p> <p><b>Cryopreservation cell medium:</b> Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.</p> <p><b>Culture medium:</b> F-12K + 10% FBS</p> <p><b>Initial handling guidelines:</b> Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.</p> <ol style="list-style-type: none"> <li>1. Thaw the vial in 37°C water bath approximately 1-2 minutes.</li> <li>2. Transfer the cell suspension (0.8 ml) to a 15 ml/50 ml conical sterile polypropylene centrifuge tube containing 8.4 ml pre-warmed <b>culture medium</b>, wash vial with an additional 0.8 ml <b>culture medium</b> (total volume 10 ml) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 ml represents minimum recommended dilution. 20 ml represents maximum recommended dilution.</li> <li>3. Resuspend the cell pellet in 5 ml pre-warmed <b>culture medium</b> and count using a haemocytometer (<a href="#">Click here to view haemocytometer protocol</a>) or alternative cell counting method. Based on cell count, seed cells in an appropriate cell culture flask at a density of <math>2 \times 10^4</math> cells/cm<sup>2</sup>. This should allow for confluency within 48 hours. Seeding density is given as a guide only and should be scaled to align with individual lab schedules.</li> <li>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Cultures should be monitored daily.</li> </ol> <p><b>Subculture guidelines:</b></p> <p>All seeding densities should be based on cell counts gained by established methods. A guide seeding density of <math>2 \times 10^4</math> cells/cm<sup>2</sup> is recommended for confluency (80-90% confluence) within 48 hours.</p> <p>A partial media change 24 hours prior to subculture may be helpful to encourage growth, if required.</p> <p>Cells should be passaged when they have achieved 80-90% confluence.</p> <p><a href="#">Click here to view the Mammalian cell tissue culture protocol</a></p>

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our [limited use license](#) and [patent pages](#).

## Properties

---

<b>Number of cells</b>	1 x 10 <sup>6</sup> cells/vial, 1 mL
<b>Viability</b>	~90%
<b>Adherent /Suspension</b>	Adherent
<b>Tissue</b>	Lung
<b>Cell type</b>	epithelial
<b>Disease</b>	Carcinoma
<b>Gender</b>	Male
<b>Mycoplasma free</b>	Yes
<b>Storage instructions</b>	Shipped on Dry Ice. Store in liquid nitrogen.
<b>Storage buffer</b>	Constituents: 8.7% DMSO, 2% Cellulose, methyl ether

## Target

---

<b>Function</b>	Acetylates histones, giving a specific tag for transcriptional activation. Also acetylates non-histone proteins, like NCOA3 coactivator. Binds specifically to phosphorylated CREB and enhances its transcriptional activity toward cAMP-responsive genes. Acts as a coactivator of ALX1 in the presence of EP300.
<b>Involvement in disease</b>	Note=Chromosomal aberrations involving CREBBP may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with MYST3/MOZ; translocation t(11;16)(q23;p13.3) with MLL/HRX; translocation t(10;16)(q22;p13) with MYST4/MORF. MYST3-CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Defects in CREBBP are a cause of Rubinstein-Taybi syndrome type 1 (RSTS1) [MIM:180849]. RSTS1 is an autosomal dominant disorder characterized by craniofacial abnormalities, broad thumbs, broad big toes, mental retardation and a propensity for development of malignancies.
<b>Sequence similarities</b>	Contains 1 bromo domain. Contains 1 KIX domain. Contains 2 TAZ-type zinc fingers. Contains 1 ZZ-type zinc finger.
<b>Domain</b>	The KIX domain mediates binding to HIV-1 Tat.
<b>Post-translational modifications</b>	Methylation of the KIX domain by CARM1 blocks association with CREB. This results in the blockade of CREB signaling, and in activation of apoptotic response. Phosphorylated upon DNA damage, probably by ATM or ATR. Sumoylation negatively regulates transcriptional activity via the recruitment of DAAX.
<b>Cellular localization</b>	Cytoplasm. Nucleus. Recruited to nuclear bodies by SS18L1/CREST. In the presence of ALX1 relocalizes from the cytoplasm to the nucleus.

---

**Please note:** All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

## **Our Abpromise to you: Quality guaranteed and expert technical support**

---

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
  
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

## **Terms and conditions**

---

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors